A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200 mg BID) for 10 days Compared with Fidaxomicin (200 mg BID) for 10 days for the Treatment of Clostridium difficile Infection (CDI)

Trial Profile

A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200 mg BID) for 10 days Compared with Fidaxomicin (200 mg BID) for 10 days for the Treatment of Clostridium difficile Infection (CDI)

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2017

At a glance

  • Drugs Ridinilazole (Primary) ; Fidaxomicin
  • Indications Clostridium infections
  • Focus Adverse reactions
  • Acronyms CoDIFy 2
  • Sponsors Summit Therapeutics
  • Most Recent Events

    • 09 Oct 2017 Results from this trial were presented at IDWeek 2017, according to a Summit Therapeutics media release.
    • 08 Oct 2017 Results presented at the IDWeek 2017
    • 05 Sep 2017 Top-line results presented in a Summit Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top